Atomo Diagnostics Wins Exclusive Global Licence for Rapid Liver Function Test on Pascal Platform

Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an announcement.

Atomo Diagnostics has secured an exclusive global licence from the Burnet Diagnostics Initiative for a novel liver function test that detects liver injury via alanine aminotransferase (ALT) using Atomo’s Pascal point-of-care cassette. The test, which is already substantively developed and undergoing evaluation by a large multinational pharmaceutical company in a US drug trial for drug-induced liver injury monitoring, positions Atomo to tap into a significant global market for rapid liver function screening and monitoring, including chronic liver diseases such as viral hepatitis, fatty liver and alcoholic liver disease. The agreement, which runs to the expiry of the underlying patents expected in 2044, builds on Atomo’s existing collaboration with Burnet and includes a $150,000 upfront licensing milestone payment plus performance-based regulatory milestone payments, while standard industry royalties will only commence once regulatory approvals are secured in key markets, lowering development risk and providing a clearer path to commercialisation.

The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.

More about Atomo Diagnostics Ltd.

Atomo Diagnostics Limited is an Australian medical diagnostics company specialising in rapid point-of-care and at-home testing solutions, built around its proprietary Pascal cassette platform. Its products target high-need clinical areas where quick, easy-to-use tests can support real-time decision-making for healthcare providers, pharmaceutical companies and patients globally.

Average Trading Volume: 1,172,306

Technical Sentiment Signal: Buy

Current Market Cap: A$29.17M

Learn more about AT1 stock on TipRanks’ Stock Analysis page.